DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DIOVAN HCT

Summary for Tradename: DIOVAN HCT

Patents:1
Applicants:1
NDAs:1
Suppliers: see list9
Formulation / Manufacturing:see details
drug
patent expirations by year for
 DIOVAN HCT

Pharmacology for Tradename: DIOVAN HCT

Clinical Trials for: DIOVAN HCT

Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Status: Completed Condition: Hypertension

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
Status: Completed Condition: Hypertension

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
Status: Completed Condition: Hypertension

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
Status: Completed Condition: Hypertension

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
Status: Completed Condition: Hypertension

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage
Status: Completed Condition: Hypertension; Ventricular Remodeling; Erectile Dysfunctions

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
Status: Completed Condition: Hypertension

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)
Status: Completed Condition: Healthy Normotensive Participants

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide
Status: Completed Condition: Healthy Normotensive Participants

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
Status: Completed Condition: Hypertension; Hypertrophy, Left Ventricular

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
DIOVAN HCT
hydrochlorothiazide; valsartan
TABLET;ORAL020818Apr 28, 2006RXNo6,294,197*PED<disabled>Y<disabled>
Novartis
DIOVAN HCT
hydrochlorothiazide; valsartan
TABLET;ORAL020818Apr 28, 2006RXYes6,294,197*PED<disabled>Y<disabled>
Novartis
DIOVAN HCT
hydrochlorothiazide; valsartan
TABLET;ORAL020818Jan 17, 2002RXNo6,294,197*PED<disabled>Y<disabled>
Novartis
DIOVAN HCT
hydrochlorothiazide; valsartan
TABLET;ORAL020818Mar 6, 1998RXNo6,294,197*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DIOVAN HCT

Drugname Dosage Strength RLD Submissiondate
valsartan and hydrochlorothiazideTablets320 mg/12.5 mg and 320 mg/25 mgDiovan HCT2/7/2007
valsartan and hydrochlorothiazideTablets80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mgDiovan HCT12/2/2005

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc